Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

P21‐activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells

4 Jan 2017

Abstract excerpt

BRAF is a commonly mutated oncogene in various human malignancies and a target of a new class of anti-cancer agents, BRAF-inhibitors (BRAFi). The initial enthusiasm for these agents, based on the early successes in the management of metastatic melanoma, is now challenged by the mounting evidence of intrinsic BRAFi-insensitivity in many BRAF-mutated tumors, by the scarcity of complete responses, and by the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Melanoma and MAPK Pathways
Share to Protein Kinase Regulation and GTPase Signaling

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28052407
DOI: 10.1002/mc.22611

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 22 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

P21‐activated kinase 1 regulates resistance to BRAF inhibition in human cancer cellsPMID 28052407Read ↗

PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.Semantic proximity Read ↗

[Resistance to BRAF inhibitors: A lesson from clinical observations].Semantic proximity Read ↗

The response to PAK1 inhibitor IPA3 distinguishes between cancer cells with mutations in BRAF and Ras oncogenes.Semantic proximity Read ↗

Overcoming Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutated TumoursSemantic proximity Read ↗

P21-Activated Kinase 1 (PAK1) as a Therapeutic Target in BRAF Wild-Type MelanomaSemantic proximity Read ↗

A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.Semantic proximity Read ↗

BRAFV600E negatively regulates the AKT pathway in melanoma cell lines.Semantic proximity Read ↗

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma.Semantic proximity Read ↗

PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanomaSemantic proximity Read ↗

p21-Activated Kinase 1 Is Required for Efficient Tumor Formation and Progression in a Ras-Mediated Skin Cancer ModelSemantic proximity Read ↗

AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma.Semantic proximity Read ↗

Combined blockade of mTOR and p21-activated kinases pathways prevents tumour growth in KRAS-mutated colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.